Wormin (Mebendazole) 100 mg 24 tablets

Latin name:
Vormin

Active substance Wormin:

Mebendazole

Release form Mebendazole:

tablets

Owner / Registrar Mebendazole:

CADILA PHARMACEUTICALS, Ltd.
International Classification of Diseases (ICD-10) B67
Echinococcosis B68
Teniosis B75
Trichinosis B76
Ankylostomiasis B77
Ascariasis B78
Strongyloidosis B79
Trichuroz B80
Enterobiasis

Pharmacological group Wormin:

Anthelmintic drug

pharmachologic effect Wormin:

Broad-spectrum anthelmintic agent; the most effective for enterobiasis. Causes irreversible disruption of glucose utilization in the helminth's body and inhibits the synthesis of ATP.

Pharmacokinetics:

The Medicine is practically not absorbed in the gastrointestinal tract. The drug binds to plasma proteins and is 90%.
Wormin is unevenly distributed in organs, accumulates in adipose tissue, liver and helminth larvae. In the liver, the drug is metabolized to a 2-amino derivative.

T1 / 2 - 2.5-5.5 hours. More than 90% of the drug dose is excreted in the feces unchanged, the absorbed part (5-10%) is excreted by the kidneys.

special instructions Wormin:

With prolonged use, it is necessary to monitor the peripheral blood picture, liver and kidney function.
Avoid drinking alcohol for 24 hours after taking mebendazole.
Do not use a laxative after taking Medicine
Periodic examination of smears of the anal area and feces after the end of treatment is mandatory (therapy is considered effective in the absence of helminths or their eggs for 7 consecutive days).
In case of impaired liver function
Contraindicated in severe liver dysfunction.
Application during pregnancy and lactation
Contraindicated for use during pregnancy and lactation (breastfeeding).

Drug interactions Mebendazole:

Mebendazole reduces the need for insulin in diabetic patients.
Avoid co-administration of Medicine with lipophilic substances. With the simultaneous use of cimetidine can increase, and carbamazepine and other inducers of metabolism - reduce the concentration of mebendazole in the blood.